Prometedor tratamiento con denosumab contra el cáncer de mama

The preliminary results of the clinical study d-biomark against breast cancer, promoted by the Catalan Institute of Oncology (ICO), revealed the potential of denosumab, an osteoporosis treatment, against breast cancer.

Published in «Breast Cancer Research,» it emphasizes that denosumab could increase the anti-tumor immune response by increasing the number of infiltrating immune cells to combat cancer, as reported by Belvindge Biomedical Research (Idibell) on Tuesday.

The research is based on some promising previous results in basic and preclinical research, where it was demonstrated that inhibiting the RANK pathway could help stop tumor growth.

In this clinical study, the biological effects of denosumab were evaluated in 60 women with early-stage breast cancer, newly diagnosed, who had not yet started any treatment and were all pending surgery for tumor removal.

Two doses of 120 milligrams of denosumab were administered in the treatment group and no treatment in the control group, then blood samples and biopsies were compared at the time of diagnosis with those after the injection.

Although denosumab was not associated with a reduction in the proliferation or survival of cancer cells, it was related to a «significant» growth of immune cells infiltrating the tumors.

Therefore, growth was observed in all subtypes of breast cancer evaluated, but especially in luminal B tumors.

The researchers point out that the ability to increase immune infiltration into the tumor «opens up valuable clinical interest,» so after these results, a new analysis has been launched to discover the mechanisms involved in this immune activation.

FUENTE